Advertisement
Screener

Vir Biotechnology, Inc. (VIR) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Vir Biotechnology, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Vir Biotechnology, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $391.78M went out.
  • Fiscal year ended 2025-12-31: from investing, $310.37M came in.
  • Fiscal year ended 2025-12-31: from financing, $3.79M came in.
  • Fiscal year ended 2025-12-31: change in cash, $77.63M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldOtherNot split outChange in cash
2025-12-31-$391.78M$310.37M$1.35M-$361.00K$2.80M*-$77.63M
2024-12-31-$446.35M$499.37M$790.00K-$165.00K$3.76M*$57.40M
2023-12-31-$778.78M$164.63M$3.48M-$287.00K$4.28M*-$606.68M
2022-12-31$1.66B-$1.19B$4.53M-$260.00K$30.49M*$504.55M
2021-12-31-$47.59M-$140.81M$13.08M$87.25M*-$88.07M
2020-12-31-$190.94M-$9.86M$323.21M$206.26M*$328.67M
2019-12-31-$129.63M-$256.16M$126.41M$322.83M*$63.45M
2018-12-31-$94.10M-$60.44M$584.00K$24.39M*-$129.56M
2017-12-31-$66.38M-$29.99M$271.18M*$174.81M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldOtherNot split outChange in cash
2026-06-30$123.33M*-$197.14M*$1.44M*$76.94M*
2026-03-31-$132.39M$11.84M$162.35M$41.97M
2025-12-31-$25.88M*$86.65M*$1.00K*-$2.00K*$1.04M*
2025-09-30-$167.57M*$40.45M*$101.00K*$1.00K*
2025-06-30-$120.22M*$56.46M*$649.00K*$1.40M*
2025-03-31-$78.12M$126.82M$0.00$598.00K*$49.30M
2024-12-31-$87.64M*$140.74M*$89.00K*$13.00K*$1.16M*
2024-09-30-$171.48M*$118.60M*$71.00K*-$40.00K*
2024-06-30-$77.85M*$211.61M*$409.00K*$2.53M*
2024-03-31-$109.39M$28.42M$221.00K-$80.82M
2023-12-31-$107.93M*-$104.81M*$89.00K*$1.59M*
2023-09-30-$155.83M*-$58.95M*$343.00K*
2023-06-30-$389.25M*$230.31M*$742.00K*$2.44M*
2023-03-31-$125.78M$98.08M$2.31M-$25.36M
2022-12-31$35.13M*-$153.13M*$932.00K*$1.08M*
2022-09-30$117.90M*-$662.61M*$2.04M*
2022-06-30$960.14M*-$272.33M*$1.07M*$2.01M*
2022-03-31$550.09M-$105.39M$484.00K$27.20M*$472.38M
2021-12-31$7.70M*-$377.58M*$3.44M*$2.23M*
2021-09-30-$105.81M*$73.86M*$3.69M*
2021-06-30$140.06M*$75.38M*$3.59M*
2021-03-31-$89.53M$87.53M$2.35M$85.15M*$85.51M
2020-12-31-$82.05M*$60.71M*$0.00*
2020-09-30-$49.84M*-$185.38M*$116.52M*$207.79M*
2020-06-30-$10.64M*$10.59M*$2.25M*$203.09M*
2020-03-31-$48.41M$104.22M$143.00K$55.90M
2019-12-31-$38.88M*-$73.77M*$63.00K*$130.04M*
2019-09-30-$36.95M*$47.29M*$364.00K*$1.37M*
2019-06-30-$24.30M*$44.48M*$635.00K*
2019-03-31-$29.49M-$274.16M$67.00K$317.34M*$13.76M
2018-12-31-$29.51M*$16.10M*$259.00K*$10.18M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Vericel Corp (VCEL)United States$2.011B93.97
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40